This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only trea…

Grade 2 IDH1-mutant GliomaGrade 3 IDH1-mutant GliomaGlioma+5 more

~Estimated

~$10 – $8,750

Nuvation Bio Inc.NCT07703436

Phase 3

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in part…

GliomaAstrocytoma, Grade IVIDH1-mutant Glioma+5 more

~Estimated

~$10 – $8,750

Nuvation Bio Inc.NCT05303519